Browsing Tag
rituximab
13 posts
FDA authorizes breakthrough Epkinly regimen from AbbVie for relapsed or refractory follicular lymphoma
Discover how AbbVie’s newly approved Epkinly regimen with rituximab and lenalidomide is redefining treatment for relapsed or refractory follicular lymphoma.
November 18, 2025
Is Dr. Reddy’s oncology pipeline strong enough to compete with global innovators in 2025 and beyond?
Explore Dr. Reddy’s oncology pipeline, biosimilars approvals, and revenue outlook—can the Hyderabad-based pharma firm compete with global cancer drug innovators?
July 15, 2025
Can Dr. Reddy’s build a biosimilars portfolio that rivals Biocon and global MNCs in regulated markets?
Explore Dr. Reddy’s biosimilars pipeline, regulatory milestones, and commercial strategy—can it compete with Biocon and global pharma giants in 2025?
June 24, 2025
Dr. Reddy’s Laboratories secures key European endorsement for Rituximab biosimilar
In a significant development for the pharmaceutical industry, Dr. Reddy’s Laboratories Ltd. has received a positive opinion from…
July 30, 2024
FDA accepts review of Dr. Reddy’s biosimilar rituximab candidate, DRL_RI
Dr. Reddy’s Laboratories, an Indian pharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted…
July 12, 2023
Dr. Reddy’s Tocilizumab biosimilar shows promising results in phase 1 trial
Dr. Reddy’s Laboratories, an Indian pharmaceutical company, announced a significant milestone as its tocilizumab biosimilar candidate, DRL_TC, successfully…
June 5, 2023
BeiGene gets Brukinsa FDA approval for chronic lymphocytic leukemia
BeiGene has secured the approval of the US Food and Drug Administration (FDA) for the company’s Brukinsa (zanubrutinib)…
January 21, 2023
Ipsen to acquire American biopharma company Epizyme for $247m
French pharma company Ipsen has agreed to acquire Epizyme, a Massachusetts-based commercial-stage biopharma company for an initial consideration…
June 27, 2022
Chronos-3 trial results : Aliqopa, rituximab combo meets primary endpoint of PFS, says Bayer
Chronos-3 trial results : Bayer said that the investigational combination of Aliqopa (copanlisib) and rituximab considerably increased progression-free…
April 11, 2021
Amgen, Allergan file BLA to FDA for Rituxan biosimilar ABP 798
Rituxan biosimilar ABP 798 : US biopharma company Amgen and Irish pharma company Allergan have submitted a Biologics…
December 20, 2019